Management of Attention-Deficit/Hyperactivity Disorder in Transitional-Aged Youth With Comorbid Substance Use Disorder

Attention-deficit/hyperactivity disorder (ADHD) frequently co-occurs with substance use disorder (SUD), particularly in transitional-age youth, presenting complex diagnostic and therapeutic challenges. ADHD increases the risk of developing a SUD through multiple pathways, including biological, psycho-social, and familial or genetic factors. The presence of SUD can exacerbate ADHD symptoms and reduce treatment adherence, creating a reinforcing cycle of impairment. Early and sustained ADHD treatment has been associated with reduced SUD risk and improved treatment retention. Accurate diagnosis requires comprehensive evaluation strategies that account for symptom overlap and comorbidities. Long-acting or prodrug stimulant formulations, non-stimulant pharmacotherapies, and integrated psychosocial interventions, including motivational interviewing and cognitive-behavioral therapy, play vital roles in management. Clinicians must balance the need for symptom control with diversion concerns related to central nervous system stimulants through patient education, careful medication selection, limiting or monitoring supply of medication, and secure storage recommendations. An integrated, multi-modal approach can improve outcomes and mitigate long-term risks associated with both ADHD and SUD.